marked.bio

ROS1 TKI · small molecule

JYP0322

3 active trials, targeting ROS1. Not approved for any biomarker on marked.bio yet.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Biomarkers

BiomarkerActive trialsAll trialsFurthest active phase
ROS1 fusion 3 3 Phase 3

Sponsors

Industry sponsors leading active biomarker-selected trials of JYP0322.

  1. Guangzhou JOYO Pharma 3

Trials

3 of 3 trials shown

  1. A Phase III Study to Evaluate the Efficacy and Safety of JYP0322 in Previously Untreated ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer

    Not yet recruiting Phase 3 Guangzhou JOYO Pharma Started 2026Primary completion 2028-12 NCT07816380

    JYP0322crizotinib FDA EU

    …dition stage IIIB or IIIC not amenable to multimodality therapy) or metastatic (stage IV) ROS1-positive non-small cell lung cancer (NSCLC).

    ROS1 fusionNSCLC (Advanced Non-small Cell Lung Cancer)

  2. JYP0322 Versus Platinum Based Doublet Chemotherapy in ROS1 Positive Patients Previously Treated With ROS1-TKIs.

    Not yet recruiting Phase 3 Guangzhou JOYO Pharma Started 2025Primary completion 2027-10 NCT07154368

    pemetrexedJYP0322

    Locally advanced or metastatic ROS1 fusion positive NSCLC.

    ROS1 fusionNon Small Cell Lung Cancer

  3. Phase I Study of JYP0322 in ROS1 Fusion-Positive Solid Tumors

    Recruiting Phase 1 Guangzhou JOYO Pharma Started 2022Primary completion 2026-06 NCT06128148

    JYP0322

    Phase I Study of JYP0322 in ROS1 Fusion-Positive Solid Tumors

    ROS1 fusionProtein Kinase Inhibitors, Other Protocol Specified Criteria, Lung Neoplasms, Brain Neoplasms